Inactive Instrument

Highlights Cytori Therapeutics Inc Nasdaq

Equities

US23283K2042

Highlights

Unlock all the news: Be the first to know and act before the market!

Plus Therapeutics to Receive $3.3 Million Advance Payment From CPRIT For Radiotherapeutic Development Program	07/06	MT
Plus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Plus Therapeutics, Inc. acquired CNSide, a leptomeningeal metastases diagnostic platform.	09/05	CI
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	25/03	CI
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	11/03	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
North American Morning Briefing : S&P 500 Futures -2-	05/03	DJ
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	20/11	CI
Plus Therapeutics, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023 and Calendar Year of 2024	01/23/01	CI
Plus Therapeutics, Inc. announces an Equity Buyback for $0.5 million worth of its shares.	01/23/01	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/23/01	CI
Plus Therapeutics, Inc. authorizes a Buyback Plan.	31/23/31	CI
Plus Therapeutics, Inc. Completes Dosing in Cohort 4 of ReSPECT-LM Phase 1 Clinical Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	10/23/10	CI
Biocept Signs Non-Exclusive Licensing Agreement With Plus Therapeutics on CNSide Tumor Cell Platform	08/23/08	MT
Plus Therapeutics, Inc. Initiates Part B of ReSPECT-LM Phase 1/2a Trial for Leptomeningeal Metastase	05/23/05	CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.	15/23/15	CI
Tranche Update on Plus Therapeutics, Inc.'s Equity Buyback Plan announced on August 15, 2022.	15/23/15	CI
Plus Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Plus Therapeutics, Inc.'s Equity Buyback announced on August 15, 2022 has expired with 0 shares, representing 0% for $0 million.	14/23/14	CI
Plus Therapeutics Says Leptomeningeal Metastases Phase 1 Trial of Rhenium Obisbemeda Showed Lower Tumor Cell Counts	11/23/11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Cytori Therapeutics Inc Nasdaq

Equities

US23283K2042

Highlights

Filters